What Happened?
Shares of biotech company Regeneron (NASDAQ: REGN) fell 7.1% in the afternoon session after its first-quarter 2026 earnings report revealed significant profitability concerns that overshadowed beats on revenue and earnings per share.
The company reported revenue of $3.61 billion and adjusted earnings of $9.47 per share, surpassing Wall Street's estimates. However, investor sentiment soured due to a sharp decline in profitability. Adjusted operating income came in at $642.9 million, a staggering 32.4% below analyst expectations. This was reflected in the adjusted operating margin, which contracted to 17.8% from 19.5% in the same quarter last year.
Furthermore, the company's free cash flow margin also declined, pointing to persistent struggles with efficiency. The market's negative reaction suggests that the headline beats were not enough to outweigh concerns about the company's deteriorating underlying profitability.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Regeneron? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Regeneron’s shares are not very volatile and have only had 6 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The previous big move we wrote about was 27 days ago when the stock dropped 3% on the news that reports revealed that the US may impose up to 100% tariffs on imports of branded and patented drugs.
This potential move would target pharmaceutical companies that have not negotiated deals to lower drug prices in the United States. The news sparked a significant sell-off in the sector, with the Nifty Pharma index declining over 5% as all its constituent stocks traded lower. The concerns were particularly pronounced for international drugmakers who rely on the US market.
Regeneron is down 11.7% since the beginning of the year, and at $685.72 per share, it is trading 15.6% below its 52-week high of $812.27 from January 2026. Despite the year-to-date decline, investors who bought $1,000 worth of Regeneron’s shares 5 years ago would now be looking at an investment worth $1,414.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
